RNA sequencing has become a standard tool across drug discovery, translational research, and biomarker development. It allows researchers to measure how cells respond to disease, treatment, or genetic changes at scale.
But sequencing alone does not answer biological questions.
The real challenge is understanding which genes change, how meaningful those changes are, and what they tell you about the system you are studying. This is where Differential Gene Expression (DGE) analysis becomes important.
DGE analysis helps researchers connect RNA-seq data to mechanisms, target biology, and treatment response. In this blog, we break down what differentially expressed genes are, why they matter, and how to analyze them properly in both bulk and single-cell RNA-seq.
Jump to a section in this blog:
- What is a differentially expressed gene?
- Why DEGs matter in drug discovery
- Why do bulk and single-cell DGE need different approaches
- Bulk RNA-seq DGE: strong signal across populations
- Single-cell RNA-seq DGE: finding biology that bulk can miss
- A DEG list is only the start
- Common mistakes in DGE analysis
- Turning RNA-seq data into decisions
What is a differentially expressed gene?
A differentially expressed gene, or DEG, is a gene whose expression level changes between two biological conditions.
This could mean:
- Healthy versus diseased tissue
- Before and after treatment
- Sensitive versus resistant cell models
RNA-seq measures how many transcripts each gene produces. DGE analysis compares these counts between groups and tests whether those differences are consistent enough to be biologically meaningful.
Two metrics are central here:
- Log₂ fold change (log₂FC): how much expression changes
- False discovery rate (FDR): how likely that change is to be real after correcting for thousands of tests
Together, they help separate true biological shifts from background noise.
For teams in pharma and biotech, this is often the first step in understanding how a perturbation changes cellular state.
Why DEGs matter in drug discovery
DEGs are not just outputs from an analysis pipeline. They often shape the next experimental question.
1. Understanding the mechanism
Changes in gene expression can show which pathways respond to a drug, mutation, or disease state.
This helps confirm whether a system behaves as expected or whether something unexpected is happening.
That matters early in screening and later when validating lead compounds.
2. Identifying biomarkers
Some expression changes are highly reproducible. That makes them useful as biomarkers.
They can support:
- Patient stratification
- Response prediction
- Disease monitoring
This is especially relevant in oncology and immunology, where molecular context often drives clinical outcome.
3. Finding new targets
Not every useful target is obvious at the phenotype level.
DGE can uncover genes that become active only in a disease state or in response to treatment pressure.
These can point to compensatory pathways, resistance mechanisms, or entirely new vulnerabilities.
4. Guiding downstream experiments
DEG lists often shape what happens next.
That could mean CRISPR validation, proteomics, spatial follow-up, or functional assays.
In practice, they help narrow the search space and make downstream work more focused.
Want to see how differential gene expression can uncover drug response in patient-derived organoid models?
Download our DRUG-seq organoid tech note to explore how transcriptomic phenotyping reveals additive treatment effects and actionable gene signatures.
Why do bulk and single-cell DGE need different approaches
The way you analyze differential expression depends heavily on how the experiment was designed.
This is one of the biggest differences between bulk and single-cell RNA-seq.
In bulk RNA-seq, each sample gives you one averaged measurement across many cells. Most experiments include biological replicates, which makes statistical comparisons between conditions relatively straightforward.
Single-cell RNA-seq works differently. Instead of averaging across cells, it measures each cell individually. This gives much higher resolution, but it also introduces more noise and complexity. Often, projects have many cells but only a small number of biological samples.
That changes the statistics. If you ignore this and apply bulk assumptions directly to single-cell data, you can overestimate significance and misread biological effects.
This is why assay choice and analysis strategy should always be considered together.
Bulk RNA-seq DGE: strong signal across populations
Bulk RNA-seq remains one of the most reliable ways to detect expression changes at the population level.
It is widely used for:
- Compound screening
- Toxicology studies
- Target validation
- Mechanism-of-action work
It works best when you care about the average response across a sample.
Core workflow
Step 1: Build the count matrix
The first step is to map reads and assign them to genes.
This converts raw sequencing files into count tables.
Step 2: Normalize the data
No two libraries are identical.
Sequencing depth and complexity vary, so normalization makes samples comparable.
Step 3: Correct for technical variation
Batch effects can introduce patterns that have nothing to do with biology.
Differences in reagent lots, operators, or sequencing runs can all influence the data.
Correcting this early improves confidence later.
Step 4: Test for differential expression
Tools like DESeq2 and edgeR model count distributions and estimate which genes change significantly.
These methods remain widely used because they handle biological variability well.
Step 5: Review quality before interpreting results
PCA, MA-plots, and outlier checks help catch issues before they affect conclusions.
In preclinical settings, bulk DGE often provides the first molecular readout of treatment effect.
Want to see differential gene expression analysis applied in a real high-throughput drug perturbation workflow?
Download our DRUG-seq tech note to explore how transcriptomic phenotyping uncovers dose-dependent responses at scale.
Single-cell RNA-seq DGE: finding biology that bulk can miss
Bulk RNA-seq gives you an average. That average can hide important cell-specific responses. Single-cell RNA-seq makes those visible.
This matters in systems where heterogeneity drives biology, such as:
- Tumour microenvironments
- Immune populations
- Cell therapies
- Complex organoids
A small resistant subpopulation may be invisible in bulk but biologically critical. Single-cell DGE can identify that.
Key challenges
Single-cell data brings its own complications:
- Sparse counts
- Many zero values
- Limited donor replication
- Stronger batch effects
These are normal, but they change how you interpret the signal.
Practical workflow
Step 1: Filter and normalize cells
Remove low-quality cells and likely doublets.
Then normalize to reduce technical noise.
Step 2: Integrate batches
If samples come from multiple donors or runs, integration is often necessary.
This helps align biology while reducing technical differences.
Step 3: Choose the right testing strategy
Two approaches are common.
Pseudobulk combines counts per donor and cell type before testing. This usually yields the most robust results when replicates are available.
Per-cell testing compares cells directly. This is often used in exploratory studies with limited donor numbers.
Each approach has trade-offs.
Step 4: Set realistic thresholds
Single-cell expression shifts are often smaller than bulk.
Small fold changes can still be biologically important.
Step 5: Confirm what you found
Marker validation and reference mapping help ensure clusters and DEGs make biological sense.
For immunotherapy and cell therapy programs, this level of resolution can change how you prioritize candidates.
A DEG list is only the start
Finding DEGs is useful. Understanding them is what creates value. A list of genes only becomes informative when you place it in a biological context.
That often means:
- Pathway enrichment
- Gene ontology analysis
- Reference atlas mapping
- Spatial context
- Multi-omics integration
This helps answer bigger questions. Are these genes part of the same pathway? Do they point to a resistance program? Are they linked to a specific cell state?
That is how transcriptomic data becomes interpretable. And that is usually where the most important decisions begin.
Common mistakes in DGE analysis
Even good datasets can lead to weak conclusions if the analysis design is off.
Common mistakes include:
- Treating technical replicates as biological replicates
- Ignoring batch effects
- Overlooking donor identity in single-cell analysis
- Focusing on p-values without considering effect size
- Treating a DEG list as a final result instead of a starting point
These issues are common and avoidable.
Turning RNA-seq data into decisions
DGE analysis sits at the center of many research workflows because it helps connect molecular change to biological meaning.
For biotech and pharma teams, this can support target selection, compound profiling, biomarker discovery, and translational decision-making.
But the quality of those decisions depends on how the data is generated, analyzed, and interpreted. That is why experimental design matters as much as sequencing depth.
At Single Cell Discoveries, we work with research teams to design RNA-seq experiments, process complex datasets, and interpret differential expression in the right biological context.
Because the goal is rarely just to find changing genes. It is to understand what those changes mean, and what to do next.
Information Guide Discovery-seq
Discover our Discovery-seq service
Explore how Discovery-seq, our high-throughput DRUG-seq service, uncovers dose-dependent transcriptional changes, reveals mechanisms of action, and helps turn DEG lists into actionable biological insights.
